A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models

Previous studies show that cyclophilins contribute to many pathologic processes, and cyclophilin inhibitors demonstrate therapeutic activities in many experimental models. However, no drug with cyclophilin inhibition as the primary mode of action has advanced completely through clinical development...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Joseph, Bobardt, Michael, Chatterji, Udayan, Mayo, Patrick R., Trepanier, Daniel J., Foster, Robert T., Gallay, Philippe, Ure, Daren R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Pharmacology and Experimental Therapeutics 2019
Materias:
Gastrointestinal, Hepatic, Pulmonary, and Renal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815936/
https://www.ncbi.nlm.nih.gov/pubmed/31406003
http://dx.doi.org/10.1124/jpet.119.261099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815936/
https://www.ncbi.nlm.nih.gov/pubmed/31406003
http://dx.doi.org/10.1124/jpet.119.261099

Ejemplares similares